Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Astellas Pharma Inc (ALPMF)

Astellas Pharma Inc (ALPMF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.03
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.9500 +0.75%
on 02/25/20
18.1100 -11.26%
on 01/31/20
-0.8000 (-4.74%)
since 01/23/20
3-Month
15.9500 +0.75%
on 02/25/20
18.1100 -11.26%
on 01/31/20
-0.6500 (-3.89%)
since 11/19/19
52-Week
13.0000 +23.62%
on 05/08/19
18.1100 -11.26%
on 01/31/20
+1.0700 (+7.13%)
since 02/14/19

Most Recent Stories

More News
Global Immunosuppressant Drugs Market (2020 to 2025) - Featuring Astellas Pharma, Sanofi (Genzyme) & Bristol-Myers Squibb Among Others - ResearchAndMarkets.com

The "Immunosuppressant Drugs Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

ALPMF : 16.0700 (-5.58%)
BMY : 62.11 (-0.05%)
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV(TM) (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted...

ALPMF : 16.0700 (-5.58%)
SGEN : 112.17 (-0.19%)
Psoriasis Therapeutics (2020 Edition) World Market Review and Forecast to 2026 By Application, By Type, By Region, By Country (2015-2026)

(MENAFN - Ameliorate Solutions) The report titled ' Psoriasis Therapeutics Market ' has recently added by MarketInsightsReports to get a stronger and effective business outlook. It provides an in-depth...

ALPMF : 16.0700 (-5.58%)
AZN : 47.52 (+0.93%)
LLY : 133.75 (-1.23%)
MRK : 80.00 (-0.34%)
VRX.TO : 30.80 (-3.33%)
Psoriasis Therapeutics (2020 Edition) - World Market Review and Forecast to 2026 - By Application, By Type, By Region, By Country (2015-2026)

The report titled "" has recently added by MarketInsightsReports to get a stronger and effective business outlook. It provides an in-depth analysis of different attributes of industries such as trends,...

ALPMF : 16.0700 (-5.58%)
AZN : 47.52 (+0.93%)
LLY : 133.75 (-1.23%)
MRK : 80.00 (-0.34%)
VRX.TO : 30.80 (-3.33%)
XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) announced today results of the final overall survival (OS) analysis from the Phase 3 PROSPER...

ALPMF : 16.0700 (-5.58%)
PFE : 34.84 (+2.68%)
Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced the submission of a supplemental...

ALPMF : 16.0700 (-5.58%)
FGEN : 41.46 (-3.49%)
Astellas Completes Acquisition of Audentes Therapeutics

Astellas Pharma Inc. (TSE: 4503) (President and Chief Executive Officer: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has successfully completed the previously announced acquisition of Audentes...

ALPMF : 16.0700 (-5.58%)
BOLD : 59.97 (-0.02%)
Health Canada Approves Astellas' XOSPATA® (gilteritinib) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

XOSPATA is the first and only targeted treatment approved by Health Canada for patients with relapsed or refractory Acute Myeloid Leukemia with a FLT3 mutation. The approval of XOSPATA marks Astellas'...

ALPMF : 16.0700 (-5.58%)
Aptevo Therapeutics' Apvo436 Selected For Inclusion In The Leukemia & Lymphoma Society's Groundbreaking Beat Aml(R) Master Clinical Trial

APVO436 is the Latest Investigational AML Therapeutic to be Selected for Participation in the Study; Aptevo Joins Industry Leaders, Bristol-Myers Squib (formerly Celgene) Alexion Pharmaceuticals, Gilead...

AGIO : 48.40 (+3.62%)
ALXN : 94.60 (-1.60%)
ALPMF : 16.0700 (-5.58%)
CELGZ : 0.47 (+2.15%)
GILD : 74.92 (+6.88%)
APVO : 0.44 (-2.22%)
Astellas Venture Management, Pitango Venture Capital and Novartis Institutes for BioMedical Research Lead TScan Series B

TScan Therapeutics today announced the completion of its Series B raise with the inclusion of Novartis Institutes for BioMedical Research (NIBR), Pitango Venture Capital, and Astellas Venture Management...

ALPMF : 16.0700 (-5.58%)
NVS : 87.17 (-0.89%)
Trade ALPMF with:

Key Turning Points

2nd Resistance Point 16.3833
1st Resistance Point 16.2267
Last Price 16.0700
1st Support Level 15.9317
2nd Support Level 15.7933

See More

52-Week High 18.1100
Fibonacci 61.8% 16.1580
Last Price 16.0700
Fibonacci 50% 15.5550
Fibonacci 38.2% 14.9520
52-Week Low 13.0000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar